Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Cancer Biomark ; 21(4): 893-898, 2018.
Article in English | MEDLINE | ID: mdl-29439316

ABSTRACT

Colorectal cancer (CRC) is one of the most common malignant tumors in digestive tract. Previous study found close correlation between insulin-like growth factor binding proteins (IGFBPs) and occurrence of multiple tumors. This study aims to analyze the effects of IGFBP6 on the apoptosis and migration of tumor cells, and to investigate underlying mechanism. HCT-116 or SW480 cell was cultured with 1.0 mg/l, 10 mg/l and 100 mg/l IGFBP-6. MTT assay was employed to test the proliferation activity of tumor cells after differential treatment. The cell cycle of tumor cells was detected by flow cytometry, while Transwell assay was used to quantify the invasion and migration of tumor cells after IGFBP-6 intervention. In experimental group with IGFPB-6 application, the proliferation rate of HCG-116 or SW480 cells was gradually decreased with higher concentrations of IGFBP-6 (p< 0.05). The ratio of cells at G0/G1 phase was increased while S phase and G2/M phase ratio were all decreased with IGFPB-6. With further elevated concentration of IGFPB-6, there was more potency of higher G0/G1 ratio and lower S phase or G2/M phase (p< 0.05). Both invasion and migration ability of HCT-116 or SW480 cells in experimental group were decreased. With elevated IGFBP-6 concentration, cell invasion and migration were further weakened (p< 0.05).IGFBP-6 could inhibit invasion and migration of colorectal carcinoma cells possibly via inhibiting proliferation activity and arresting cell cycle of HCT-116 or SW480 cells.


Subject(s)
Biomarkers, Tumor/analysis , Colorectal Neoplasms/pathology , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Apoptosis/drug effects , Apoptosis/physiology , Cell Line, Tumor , Cell Movement/drug effects , Cell Movement/physiology , Cell Proliferation/drug effects , Cell Proliferation/physiology , HCT116 Cells , Humans , Insulin-Like Growth Factor Binding Protein 6/pharmacology
2.
Neurochem Res ; 42(2): 455-467, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27888466

ABSTRACT

IGFBP6, a member of the insulin-like growth factor-binding proteins family that contains six high affinity IGFBPs, modulates insulin-like growth factor (IGF) activity and also showed an independent effect of IGF, such as growth inhibition and apoptosis. However, the role of IGFBP6 in spinal cord injury (SCI) remains largely elusive. In this study, we have performed an acute SCI model in adult rats and investigated the dynamic changes of IGFBP6 expression in the spinal cord. Our results showed that IGFBP6 was upregulated significantly after SCI, which was paralleled with the levels of apoptotic proteins p53 and active caspase-3. Immunofluorescent labeling showed that IGFBP6 was co-localizated with active caspase-3 and p53 in neurons. To further investigate the function of IGFBP6, an apoptosis model was established in primary neuronal cells. When IGFBP6 was knocked down by specific short interfering RNA (siRNA), the protein levels of active caspase-3 and Bax as well as the number of apoptotic primary neurons were significantly decreased in our study. Taken together, our findings suggest that the change of IGFBP6 protein expression plays a key role in neuronal apoptosis after SCI.


Subject(s)
Apoptosis/physiology , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Neurons/metabolism , Spinal Cord Injuries/metabolism , Animals , Animals, Newborn , Cells, Cultured , Gene Expression Regulation , Male , Neurons/pathology , Rats , Rats, Sprague-Dawley , Spinal Cord Injuries/pathology , Thoracic Vertebrae
3.
Pituitary ; 17(6): 505-13, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24379119

ABSTRACT

BACKGROUND: Adrenocorticotrophic hormone (ACTH)-dependent Cushing's syndrome, called Cushing disease, is caused by a corticotroph tumor of the pituitary gland. Insulin-like growth factor binding protein 6 (IGFBP6), which regulates insulin-like growth factor (IGF) activity and inhibits several IGF2-dependent cancer growths, plays a pivotal role in the tumorigenesis of malignancy, but its roles in ACTH-secreting pituitary adenomas remain unclear. OBJECTIVE: To investigate IGFBP6 expression in ACTH-secreting pituitary adenomas, and its involvement in tumor growth. METHODS: Sporadic ACTH-secreting pituitary adenomas specimens (n = 41) and adjacent non-tumorous pituitary tissues (n = 9) were collected by transphenoidal surgery. IGFBP6 expression was assessed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and validated by Western blotting. Associations of IGFBP6 expression with maximum tumor diameter or Ki-67 labeling index were evaluated in ACTH-secreting pituitary adenomas. RESULTS: IGFBP6 mRNA and protein expression were both decreased in ACTH-secreting pituitary adenomas, compared to adjacent non-tumorous pituitary tissues (P < 0.01). IGFBP6 expression was correlated inversely with maximum tumor diameter (Rho = -0.53, P < 0.0001) and Ki-67 levels (Rho = -0.52, P < 0.05). Moreover, IGFBP6 downregulation activated PI3 K-AKT-mTOR pathway in ACTH-secreting pituitary adenomas. CONCLUSIONS: IGFBP6 attenuation in ACTH-secreting pituitary adenomas is associated with tumor growth, through activation of PI3K-AKT-mTOR pathway. The finding underlies IGFBP6 roles in Cushing disease and would potentially provide a novel target of medical therapies.


Subject(s)
ACTH-Secreting Pituitary Adenoma/metabolism , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Pituitary Neoplasms/metabolism , Adult , Biomarkers, Tumor/metabolism , Down-Regulation , Female , Humans , In Vitro Techniques , Ki-67 Antigen , Male , Middle Aged , Oncogene Protein v-akt/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , Young Adult
4.
Cell Tissue Res ; 353(1): 117-22, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23579552

ABSTRACT

Efficient cell expansion is a basic requirement for obtaining clinically relevant numbers of mesenchymal stem cells designed for cell-based therapies or tissue-engineering application. Previous studies have demonstrated that mesenchymal stem cells (MSC) cultivated under reduced atmospheric oxygen concentrations (2.5% O2) possess enhanced proliferation potential and can maintain their differentiation properties. We have analyzed the oxygen-dependent cytokine expression of human MSC derived from umbilical cord and attempted to link the results to the proliferation and differentiation capacities of these cells. By quantitative reverse transcription plus the polymerase chain reaction and by protein microarray, we measured the gene expression and intracellular protein concentration of several growth factors and growth factor receptors. Fibroblast growth factor-7, two growth factor receptors (vascular endothelial growth factor receptor 2 and stem cell factor receptor), and two growth-factor-binding proteins (insulin-like growth-factor-binding proteins 3 and 6) were over-expressed under hypoxic conditions, indicating that their signaling pathways participate in cell proliferation. On the other hand, typical differentiation factors such as bone morphogenetic protein-4, endothelial growth factor, and tissue growth factor-ß1 were absent in cells cultivated under hypoxic and normoxic conditions. The absolute concentration of some intracellular cytokines was also measured for the first time under hypoxia and normoxia. Our results in combination with previous findings indicate that enhanced proliferation potential and a maintained undifferentiated cell state can be ascribed to the oxygen-dependent expression of a set of cytokines. This knowledge might help in the understanding of MSC physiology and in the achievement of directed cell fate of MSC for clinical application.


Subject(s)
Cell Hypoxia/physiology , Mesenchymal Stem Cells/metabolism , Oxygen/metabolism , Umbilical Cord/metabolism , Bone Morphogenetic Protein 4/deficiency , Cell Differentiation , Cell Proliferation , Cells, Cultured , Endothelial Growth Factors/deficiency , Fibroblast Growth Factor 7/biosynthesis , Fibroblast Growth Factor 7/metabolism , Gene Expression , Humans , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/metabolism , Proto-Oncogene Proteins c-kit/biosynthesis , Proto-Oncogene Proteins c-kit/metabolism , Transforming Growth Factor beta1/biosynthesis , Umbilical Cord/cytology , Vascular Endothelial Growth Factor Receptor-2/biosynthesis , Vascular Endothelial Growth Factor Receptor-2/metabolism
5.
Neurosci Lett ; 468(3): 178-82, 2010 Jan 14.
Article in English | MEDLINE | ID: mdl-19853640

ABSTRACT

IGF-1 is an important factor for myelin synthesis and hence possesses therapeutic potential in treating demyelinating disease such as multiple sclerosis. However, IGF-1 poorly crosses the blood-brain barrier. In this study, we investigated the effects of the sex steroid progesterone and the glucocorticoid dexamethasone on regulation of the IGF-system in glial cells. By means of quantitative PCR analysis, we demonstrate that progesterone upregulates IGF-1, the type 1 IGF receptor and IGFBP-2 in primary rat astrocytes and both IGF-1 and IGFBP-6 in OLN-93 oligodendroglial progenitor cells. In contrast, dexamethasone showed a negative effect on expression of IGF-1, the type 1 IGF receptor and the respective IGF binding proteins in both cell types. In oligodendrocytes, the differentiation marker CNPase was positively regulated by progesterone and negatively regulated by dexamethasone. Further, oligodendroglial cell migration was enhanced approximately 4-fold by progesterone. This study implicates progesterone as a positive regulator of IGF-system in glial cells and demonstrates a further biological function of progesterone in oligodendrocyte biology, namely stimulation of progenitor cell migration. Dexamethasone, on the other hand, is a negative regulator of the IGF-system in glial cells.


Subject(s)
Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Insulin-Like Growth Factor I/biosynthesis , Neuroglia/drug effects , Progesterone/pharmacology , 2',3'-Cyclic-Nucleotide Phosphodiesterases/biosynthesis , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Cell Differentiation , Cell Movement , Cells, Cultured , Humans , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Neuroglia/metabolism , Oligodendroglia/cytology , Oligodendroglia/drug effects , Oligodendroglia/physiology , Progesterone/physiology , Rats , Receptor, IGF Type 1/biosynthesis , Stem Cells/cytology , Stem Cells/drug effects , Stem Cells/physiology
6.
J Biol Chem ; 284(1): 345-353, 2009 Jan 02.
Article in English | MEDLINE | ID: mdl-18957410

ABSTRACT

The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1. In this study, we identified a classical retinoic acid-responsive element in the first intron in the IGFBP-6 gene adjacent to a consensus AP-1 binding site, both elements essential for rexinoid-induced expression of IGFBP-6. In chromatin binding experiments, bexarotene increased the occupancy of the identified enhancer element by RXRalpha, RARbeta, cJun, cFos, and p300. In normal mammary epithelial cells and T47D breast cancer cells, small interfering RNA-mediated knockdown of all RXR isoforms or RARbeta, but not RARalpha or RARgamma alone, blocked the induction of IGFBP-6 by bexarotene. Simultaneous knockdown of RARalpha and RARgamma abrogated both the induction of RARbeta and the up-regulation and secretion of IGFBP-6. The suppression of either RARbeta or cJun by small interfering RNA blocked the recruitment of RXRalpha and cJun to the enhancer. These results demonstrate a novel cooperative interaction between retinoid receptors and AP-1 orchestrated by RARbeta and highlight a novel mechanism by which RARbeta can mediate the cancer-preventive effects of rexinoids.


Subject(s)
Anticarcinogenic Agents/pharmacology , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Receptors, Retinoic Acid/metabolism , Response Elements/physiology , Tetrahydronaphthalenes/pharmacology , Transcription Factor AP-1/metabolism , Bexarotene , Cell Line, Tumor , Cyclin D1/genetics , Cyclin D1/metabolism , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Gene Knockdown Techniques , Genes, fos/physiology , Humans , Insulin-Like Growth Factor Binding Protein 6/genetics , Introns/physiology , Mammary Glands, Human , Proto-Oncogene Proteins c-jun/genetics , Proto-Oncogene Proteins c-jun/metabolism , Receptors, Retinoic Acid/genetics , Retinoic Acid Receptor alpha , Retinoid X Receptor alpha/genetics , Retinoid X Receptor alpha/metabolism , Transcription Factor AP-1/genetics , p300-CBP Transcription Factors/genetics , p300-CBP Transcription Factors/metabolism , Retinoic Acid Receptor gamma
7.
Protein Pept Lett ; 14(9): 876-80, 2007.
Article in English | MEDLINE | ID: mdl-18045229

ABSTRACT

For the preparation of the complex of IGF-II and IGFBP-6, a co-expression vector containing two copies of human IGF-II and IGFBP-6 expression cassette was constructed with alcohol oxidase (AOX1) promoter and secretion signal sequence of alpha-factor, and transformed to Pichia pastoris yeast. Through a purification procedure involving anion-exchange chromatography and gel filtration, a complex of IGF-II with IGFBP-6 was obtained. An additional C-terminal sequence of IGFBP-6 (CS-BP6) was found to be bound to this complex. Dynamic light scattering showed that this complex was very stable and homogenous in solution. Western blotting based on non-reducing Tricine-SDS-PAGE indicated that IGF-II expression coupled with IGFBP-6 might significantly avoid the mispairing of disulfide bonds compared with the IGF-II expressed alone.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Protein 6/metabolism , Insulin-Like Growth Factor II/genetics , Insulin-Like Growth Factor II/metabolism , Pichia/genetics , Recombinant Fusion Proteins/isolation & purification , Base Sequence , Blotting, Western , Chromatography, Ion Exchange , Electrophoresis, Polyacrylamide Gel , Gene Expression , Genetic Vectors , Humans , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/chemistry , Insulin-Like Growth Factor II/chemistry , Insulin-Like Growth Factor II/isolation & purification , Nucleic Acid Conformation , Plasmids , Protein Folding , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics
8.
Endocrinology ; 147(5): 2399-410, 2006 May.
Article in English | MEDLINE | ID: mdl-16439447

ABSTRACT

In the present study we report the full coding sequence of rainbow trout IGF-binding protein-1 (IGFBP1), -2, -3, -5, and -6 and IGFBP-related protein-1 (IGFBP-rP1) mRNAs as well as the partial coding sequence of IGFBP-4 mRNA. To our knowledge, this is the first report of IGFBP4, IGFBP6, and IGFBP-rP1 in a nonmammalian species. The tissue distribution of all mRNAs was studied, and the ovarian expression profiles of IGFBP2 to -6 and IGFBP-rP1 between late vitellogenesis and oocyte maturation were characterized. In addition, in vitro hormonal regulation by the maturation-inducing steroid 17,20beta-dihydroxy-4-pregnen-3-one (17,20betaP), gonadotropin, and estradiol were studied. We observed that besides IGFBP1, which was only found in liver, IGFBP2 to -6 and IGFPB-rP1 were expressed in the preovulatory ovary. IGFBP3 was also detected in liver, trunk, kidney, skin, and gills, whereas IGFBP2 to -6 and IGFBP-rP1 exhibited a wider tissue distribution. In the preovulatory ovary, IGFBP3 was strongly down-regulated during the postvitellogenesis period, whereas IGFBP5 exhibited a limited up-regulation. In addition, IGFBP6 and IGFBP-rP1 were up-regulated during oocyte maturation. Hormonal regulation data indicated that all ovarian IGFBPs and IGFBP-rP1 transcripts are regulated under gonadotropic stimulation at a concentration that induced 100% oocyte maturation. In addition, IGFBP2 to -5 transcripts are regulated by 17,20betaP and estradiol. Together, our observations strongly suggest that during final oocyte maturation, a down-regulation of IGFBP3, -4, and -5 occurs in the oocyte in response to gonadotropic and 17,20betaP (IGFBP3 and -5) stimulation, whereas an up-regulation of IGFBP2 and -6 occurs in follicular layers or extrafollicular tissue in response to gonadotropic stimulation.


Subject(s)
Gene Expression Regulation, Developmental , Insulin-Like Growth Factor Binding Protein 1/biosynthesis , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 5/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Proteins/biosynthesis , Oocytes/metabolism , Vitellogenesis , Amino Acid Sequence , Animals , Cloning, Molecular , DNA, Complementary/metabolism , Estradiol/metabolism , Expressed Sequence Tags , Female , Hormones/metabolism , Liver/metabolism , Male , Molecular Sequence Data , Oncorhynchus mykiss , Ovary/metabolism , Phylogeny , RNA/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Tissue Distribution
9.
Circulation ; 112(9 Suppl): I46-50, 2005 Aug 30.
Article in English | MEDLINE | ID: mdl-16159864

ABSTRACT

BACKGROUND: Patients who undergo mechanical support with a left ventricular assist device (LVAD) exhibit reverse remodeling and in some cases recover from heart failure. We have developed a combination therapy using LVAD support combined with pharmacological therapy to maximize reverse remodeling, followed by the beta2 adrenergic agonist clenbuterol. We recently found that clenbuterol induces insulin-like growth factor I (IGF-I) in cardiac myocytes in vitro. The purpose of this study is to examine IGF-I expression in recovery patients after combination therapy. METHODS AND RESULTS: Myocardial mRNA levels were determined by real-time quantitative polymerase chain reaction in 12 recovery patients (at LVAD implantation, explantation, and 1 year after explantation). IGF-I mRNA was elevated at the time of LVAD explantation relative to donors, with 2 groups distinguishable: Those with low IGF-I mRNA at implantation who showed significant increase during recovery and those with high IGF-I mRNA at implantation who remained high. Levels returned to normal by 1 year after explantation. Microarray analysis of implantation and explantation samples of recovery patients further revealed elevated IGF-II and IGF binding proteins IGFBP4 and IGFBP6. IGF-I levels correlated with stromal cell-derived factor mRNA measured both in LVAD patients and in a wider cohort of heart failure patients. CONCLUSIONS: The data suggest involvement of elevated myocardial IGF-I mRNA in recovery. IGF-I may act to limit atrophy and apoptosis during reverse remodeling and to promote repair and regeneration in concert with stromal cell derived factor.


Subject(s)
Adrenergic beta-Agonists/therapeutic use , Clenbuterol/therapeutic use , Heart Failure/metabolism , Heart-Assist Devices , Insulin-Like Growth Factor I/biosynthesis , Adrenergic beta-2 Receptor Agonists , Cardiomyopathy, Dilated/complications , Cardiomyopathy, Dilated/surgery , Chemokine CXCL12 , Chemokines, CXC/biosynthesis , Chemokines, CXC/genetics , Combined Modality Therapy , Convalescence , Follow-Up Studies , Gene Expression Profiling , Heart Failure/drug therapy , Heart Failure/etiology , Heart Failure/genetics , Heart Failure/surgery , Humans , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor II/biosynthesis , Insulin-Like Growth Factor II/genetics , Myocardium/metabolism , Oligonucleotide Array Sequence Analysis , RNA, Messenger/biosynthesis , Regeneration , Reverse Transcriptase Polymerase Chain Reaction , Stroke Volume , Ventricular Remodeling/genetics
10.
Neuroreport ; 15(6): 1033-7, 2004 Apr 29.
Article in English | MEDLINE | ID: mdl-15076729

ABSTRACT

In the CNS insulin-like growth factor-1 (IGF-1) enhances survival of neurons, promotes myelin synthesis and acts as a mitogen for microglia. The effects of IGF-1 are regulated by a family of 6 IGF binding proteins (IGFBPs). We investigated mRNA expression patterns of IGFBPs in primary rat microglia under basal conditions and after activation with lipopolysaccharide (LPS). Under basal conditions, microglia expressed IGFBP-2 to -6, whereas, IGFBP-1 could not be detected. Following 2 h treatment with LPS mRNA levels for IGFBP-4 and -6 displayed a down regulation, and IGFBP-5 became undetectable. Levels of IGFBP-2 and -3 remained unaltered. Expression patterns of IGFBPs might play an important role in regulating the autocrine/paracrine IGF-1 actions on microglia under inflammatory conditions.


Subject(s)
Insulin-Like Growth Factor Binding Proteins/biosynthesis , Microglia/metabolism , Animals , Cells, Cultured , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Insulin-Like Growth Factor Binding Protein 1/biosynthesis , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 5/biosynthesis , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Proteins/genetics , Lipopolysaccharides/pharmacology , Microglia/drug effects , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Rats , Rats, Wistar
11.
Glia ; 44(2): 91-101, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14515325

ABSTRACT

Insulin-like growth factor 1 (IGF-1) is a growth and survival factor for oligodendrocyte lineage cells and promotes myelination. We demonstrate that IGF-binding protein 6 (IGFBP-6) is expressed and localized to the Golgi complex in rat oligodendrocyte precursor (O2A) cells. IGFBP-6 mRNA showed a developmentally regulated expression pattern, displaying a transient decrease during early development, and enhanced levels upon cell maturation. IGFBP-6 mRNA expression could be reduced by addition of basic fibroblast growth factor and progesterone while estrogen increased IGFBP-6 mRNA. IGF-1, platelet-derived growth factor, and insulin had no effect. When added exogenously, IGFBP-6 reduced O2A cell survival in the absence of IGF-1 and inhibited IGF-1-stimulated survival in a partially IGF-1-dependent and partially IGF-1-independent fashion. In addition, IGFBP-6 reduced the IGF-stimulated expression of two myelin proteins, CNPase and MAG. Taken together, the data show that IGFBP-6 is a new negative effector of oligodendrocyte survival and differentiation.


Subject(s)
Growth Inhibitors/physiology , Insulin-Like Growth Factor Binding Protein 6/physiology , Oligodendroglia/cytology , Oligodendroglia/physiology , Stem Cells/cytology , Stem Cells/physiology , 2',3'-Cyclic-Nucleotide Phosphodiesterases/antagonists & inhibitors , 2',3'-Cyclic-Nucleotide Phosphodiesterases/biosynthesis , Animals , Cell Differentiation/physiology , Cell Survival/physiology , Cells, Cultured , Gene Expression Regulation, Developmental/physiology , Growth Inhibitors/biosynthesis , Growth Inhibitors/genetics , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Myelin-Associated Glycoprotein/antagonists & inhibitors , Myelin-Associated Glycoprotein/biosynthesis , Oligodendroglia/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Stem Cells/metabolism
12.
Toxicol Lett ; 145(1): 55-68, 2003 Nov 01.
Article in English | MEDLINE | ID: mdl-12962974

ABSTRACT

Although the potent environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been well known for its immunosuppressive activity, the mechanisms of its action have been difficult to elucidate, partly because of its inability of exerting its effects in vitro. We previously reported that insulin-like growth factor-binding protein-6 (IGFBP-6) expression in the thymus was increased by TCDD treatment of mice and that the TCDD-up-regulation of the IGFBP-6 gene was also observed with EL-4 mouse thymoma cells. In the present study, we examined the effects of IGFBP-6 on the TCDD-mediated cytotoxicity in EL-4 cells. By stably expressing IGFBP-6 sense or anti-sense mRNA in the EL-4 line of mouse thymoma cells, it was possible to isolate clones in which IGFBP-6 expression was increased or decreased. Clones expressing IGFBP-6 sense mRNA displayed increased sensitivity to cytotoxicity mediated by TCDD, whereas clones expressing IGFBP-6 anti-sense mRNA displayed reduced sensitivity. TCDD-induced DNA fragmentation was less pronounced in clones expressing IGFBP-6 anti-sense mRNA than clones expressing IGFBP-6 sense mRNA or the empty vector. Caspase 3 was activated by TCDD and anti-sense IGFBP-6 expression reduced its activity. Interestingly, the effects of TCDD were exerted without aromatic hydrocarbon (Ah) receptor (AhR). Taken together, the results have shown that IGFBP-6 mediates the immunotoxic effects of TCDD in EL-4 cells in an AhR-independent pathway.


Subject(s)
Apoptosis/drug effects , Down-Regulation/drug effects , Environmental Pollutants/toxicity , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Polychlorinated Dibenzodioxins/toxicity , Receptors, Aryl Hydrocarbon/genetics , Animals , Blotting, Western , DNA Fragmentation , Deoxyribonuclease I/pharmacology , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Oligoribonucleotides, Antisense/pharmacology , Plasmids/genetics , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Tetrazolium Salts , Thiazoles , Tumor Cells, Cultured
13.
J Biol Chem ; 277(7): 5548-55, 2002 Feb 15.
Article in English | MEDLINE | ID: mdl-11719506

ABSTRACT

The zinc finger transcription factor GLI1, which mediates Sonic hedgehog signaling during development, is expressed in several human cancers, including basal cell carcinoma, medulloblastoma, and sarcomas. We identified 147 genes whose levels of expression were significantly altered in RNA obtained from cells demonstrating a transformed phenotype with stable GLI1 expression or stable Ha-ras expression. Comparison of expression profiles from GLI1- and Ha-ras-expressing cells established a set of genes unique to GLI1-induced cell transformation. Thirty genes were altered by stable GLI1 expression, and 124 genes were changed by stable Ha-ras expression. Seven genes had altered expression levels in both GLI1- and Ha-ras-expressing cells. Genes whose expression was altered by GLI1 included cell cycle genes, cell adhesion genes, signal transduction genes, and genes regulating apoptosis. GLI1 consensus DNA-binding sequences were identified in the 5' regions of cyclin D2, IGFBP-6, osteopontin, and plakoglobin, suggesting that these genes represent immediate downstream targets. Gel shift analysis confirmed the ability of the GLI1 protein to bind these sequences. Up-regulation of cyclin D2 and down-regulation of plakoglobin were demonstrated in GLI1-amplified compared with non-amplified human rhabdomyosarcoma cells. Many of the GLI1 targets with known function identified in this study increase cell proliferation, indicating that GLI1-induced cell transformation occurs through multiple downstream pathways.


Subject(s)
Oncogene Proteins/biosynthesis , Oncogene Proteins/genetics , Transcription Factors/biosynthesis , Transcription Factors/genetics , Amino Acid Motifs , Animals , Apoptosis , Base Sequence , Biotinylation , Blotting, Northern , Cell Adhesion , Cell Line, Transformed , Cyclin D2 , Cyclins/biosynthesis , Cytoskeletal Proteins/biosynthesis , DNA, Complementary/metabolism , Desmoplakins , Down-Regulation , Humans , In Situ Hybridization , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Models, Biological , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Osteopontin , Phenotype , Protein Binding , Protein Structure, Tertiary , RNA/metabolism , RNA, Messenger/metabolism , Rats , Recombinant Fusion Proteins/metabolism , Rhabdomyosarcoma/metabolism , Sialoglycoproteins/biosynthesis , Signal Transduction , Trans-Activators , Tumor Cells, Cultured , Up-Regulation , Zinc Finger Protein GLI1 , gamma Catenin , ras Proteins/biosynthesis
14.
Endocrinology ; 142(5): 1990-8, 2001 May.
Article in English | MEDLINE | ID: mdl-11316765

ABSTRACT

Insulin-like growth factor-binding proteins (IGFBPs) both stimulate and inhibit IGF activity, and in the M12 prostate cancer cell line, overexpression of IGFBP-4 was shown to delay tumorigenesis while decreasing the production of IGFBP-2. We have performed the reverse experiment, inhibition of IGFBP-4 expression with antisense complementary DNA, in two prostate tumor cell lines, ALVA-31 and M12. Expression of antisense messenger RNA transcripts was verified by RNase protection assays, and inhibition of mature IGFBP-4 in cell medium was demonstrated by Western blotting. Both transfected lines (ALVA-31asBP4 and M12asBP4) proliferated more slowly in monolayer culture than parental controls. Colony formation in soft agar was strongly inhibited in both cases, and the rate of tumor formation and growth in male athymic nude mice injected with M12asBP4 was markedly reduced relative to that in mice receiving M12 control cells. Apoptosis induced by the topoisomerase inhibitor etoposide was also enhanced in transfected cells. The effects on colony formation in soft agar and tumor formation in mice were maintained for the duration of the experiments, in contrast to the delayed growth observed in the previous study of IGFBP-4 overexpression. A significant difference was found in the patterns of IGFBP expression; production of both messenger RNA and protein for IGFBP-3 and IGFBP-6 was greatly increased in the M12asBP4 and ALVA31asBP4 cell lines. Up-regulation of these binding proteins has been observed in association with actions of 1,25-dihydroxyvitamin D(3) in prostate cancer cells, and the data suggest a role for IGFBP-3 and IGFBP-6 in the suppression of prostate tumor cell growth.


Subject(s)
DNA, Antisense/therapeutic use , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/physiology , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Prostatic Neoplasms/therapy , Animals , Apoptosis , Cell Division , Humans , Insulin-Like Growth Factor Binding Protein 4/antagonists & inhibitors , Male , Mice , Mice, Nude , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Transfection , Tumor Cells, Cultured
15.
Brain Res Mol Brain Res ; 75(2): 185-97, 2000 Feb 22.
Article in English | MEDLINE | ID: mdl-10686339

ABSTRACT

Insulin-like growth factors (IGFs) are important trophic factors during development as well as in the adult or damaged nervous system. Their trophic actions are modulated by interactions with six distinct IGF binding proteins. The mRNA expression profiles of binding proteins 2, 4 and 5 in the normal developing and adult CNS are well characterized and are shown to have distinctive, non-overlapping distributions. The IGF binding protein-6 (BP6) is also expressed in the CNS, however, details regarding its mRNA expression distribution in the developing and adult nervous system is limited. BP6 has the unique property of preferentially binding the IGF-II ligand. Coupled with the fact that this ligand is the most abundantly expressed IGF in the adult CNS, this suggests that the IGF-II/BP6 complex has a unique role in modulating IGF-II function in the adult brain. In this report the anatomical distribution of BP6 messenger RNA in the developing and adult rat nervous system is presented. In the embryonic animal the CNS expression is tightly restricted to trigeminal ganglia and, relative to the rest of the embryo, this structure has the highest expression. The expression in the forebrain and cerebellum does not occur until after postnatal day 21 and then is primarily associated with GABAergic interneurons. The highest levels of expression in the adult animal are in the hindbrain, spinal cord, cranial ganglia, and dorsal root ganglia. These nuclei in the hindbrain and periphery that express BP6 are all associated with the coordination of sensorimotor function in the cerebellum, which indicates an important role for the BP6/IGF-II complex in the function and maintenance of these systems.


Subject(s)
Brain/metabolism , Ganglia, Sensory/metabolism , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Nervous System/metabolism , Spinal Cord/metabolism , Animals , Immunohistochemistry , In Vitro Techniques , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/metabolism , RNA, Messenger/biosynthesis , Rats , Tissue Distribution , Up-Regulation
16.
Growth Horm IGF Res ; 10(6): 349-59, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11161966

ABSTRACT

Previous work has shown that neuroblastoma cells secrete IGFBP-2, -4 and -6 and that expression of these proteins is regulated by retinoic acid (at-RA) which promotes differentiation in these cells. Other agents also induce differentiation of neuroblastoma cells: these include the 9- cis and 13- cis isomers of at-RA, 1,25 dihydroxy- vitamin D3 (VD3), triidothyronine (T3) and 12-O-tetradecanoyl phorbol 13-acetate (TPA). Nine- cis and 13- cis isomers of at-RA increased IGFBP-6 expression, but decreased IGFBP-2 and IGFBP-4. VD3 stimulated IGFBP-6 and IGFBP-2 expression, whereas T3 inhibited IGFBP-6 expression without affecting IGFBP-2. TPA markedly enhanced expression of all three IGFBPs produced by SK-N-SH cells. Since IGFBP-6 secretion is associated with the arrest of proliferation in neuroblastoma cells and is regulated by the combined actions of differentiation factors, we subcloned the proximal promoter of human IGFBP-6 (nt -766/+1) into a pCAT expression vector so as to examine modulation of its transcriptional activity. VD3 and TPA were capable of stimulating promoter activity, T3 depressed it and at-RA and its 9- cis and 13- cis isomers had no effect. These results confirm the high sensitivity of IGFBP-6 expression to these differentiation agents, essentially at transcriptional level.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Neuroblastoma/metabolism , Antineoplastic Agents/pharmacology , Base Sequence , Blotting, Northern , Blotting, Western , Carcinogens , Cell Division , Chloramphenicol O-Acetyltransferase/metabolism , Cholecalciferol/pharmacology , Cloning, Molecular , Down-Regulation , Humans , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Isomerism , Luciferases/metabolism , Models, Genetic , Molecular Sequence Data , Plasmids/metabolism , Promoter Regions, Genetic , RNA/metabolism , Sequence Analysis, DNA , Tetradecanoylphorbol Acetate , Transcription, Genetic/drug effects , Tretinoin/pharmacology , Triiodothyronine/pharmacology , Tumor Cells, Cultured , Up-Regulation
17.
APMIS ; 108(11): 747-55, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11211968

ABSTRACT

The expression of the insulin-like growth factor-binding proteins (IGFBP) -3, -4, -5 and -6 was investigated in neonatal, in normal adult and in regenerating rat skeletal muscle. Semi-quantification was done by densitometric scannings of Northern blots. The expression of all investigated IGFBPs, with the exception of IGFBP-5, was higher in neonatal than in adult muscle. During postischaemic regeneration the expression of all IGFBPs increased, but with different time schedules. IGFBP-3 increased transiently during the early phase of regeneration, while IGFBP-4, -5 and -6 increased during the later phase of regeneration. In situ hybridisation on regenerating muscle showed that the expression of the various IGFBPs was cell specific; thus, IGFBP 3 was mainly expressed in macrophages, IGFBP-4 in connective tissue, IGFBP-5 in regenerating muscle cells, and IGFBP-6 in muscle cells, connective tissue and endothelium. Ligand blotting, using 125I-IGF-I as the ligand, showed a number of bands ranging between 24 and 44 kDa. Samples from neonatal and regenerating muscle contained much higher levels of all IGFBPs than those from normal adult muscle. An ordered and cell-specific expression of IGFBPs, allowing a strict regulation of IGF actions, is probably necessary to ensure an optimal regeneration process.


Subject(s)
Insulin-Like Growth Factor Binding Proteins/biosynthesis , Muscle, Skeletal/physiology , Regeneration , Animals , Animals, Newborn , Blotting, Northern , Connective Tissue/metabolism , Densitometry , Endothelium/metabolism , Gene Expression Profiling , In Situ Hybridization , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 5/biosynthesis , Insulin-Like Growth Factor Binding Protein 5/genetics , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Proteins/genetics , Ligands , Macrophages/metabolism , Male , Muscle, Skeletal/metabolism , RNA, Messenger/analysis , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley
18.
Am J Physiol ; 276(3): E536-42, 1999 03.
Article in English | MEDLINE | ID: mdl-10070021

ABSTRACT

The insulin-like growth factor (IGF) system plays an important role in skin. HaCaT human keratinocytes proliferate in response to IGFs and synthesize IGF-binding protein-3 (IGFBP-3). Recently, IGFBP-6 was also identified by NH2-terminal sequencing, but it has not been identified by Western ligand blotting. In the present study, IGFBP-6 was detected in HaCaT-conditioned medium by use of immunoblotting and Western ligand blotting with 125I-labeled IGF-II. Proteolytic activity against IGFBPs, an important mechanism for regulation of their activity, was then studied. An acid-activated, cathepsin D-like protease that cleaved both IGFBP-6 and IGFBP-3 was detected. Although proteolysis did not substantially reduce the size of immunoreactive IGFBP-6, it greatly reduced the ability of IGFBP-6 to bind 125I-IGF-II as determined by Western ligand blotting and solution assay. HaCaT keratinocytes do not express IGF-I mRNA, but IGF-II mRNA and protein expression was detected. These observations suggest the possibility of an autocrine IGF-II loop that is regulated by the relative expression of IGF-II, IGFBP-3, and IGFBP-6, and IGFBP proteases in these keratinocytes, although demonstration of this loop requires further study.


Subject(s)
Cathepsin D/metabolism , Insulin-Like Growth Factor Binding Protein 6/metabolism , Insulin-Like Growth Factor II/metabolism , Keratinocytes/metabolism , Acids/pharmacology , Cell Line , Humans , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor I/biosynthesis , Pepstatins/pharmacology , Protease Inhibitors/pharmacology
19.
J Endocrinol ; 157(2): 327-36, 1998 May.
Article in English | MEDLINE | ID: mdl-9659296

ABSTRACT

IGF-I has been proposed as a key regulator of mammary epithelial cell (MEC) growth and differentiation. As IGF-I bioactivity is modulated by specific, high-affinity binding proteins (IGFBP), the forms of IGFBP that are secreted by the bovine MEC line, MAC-T, were identified. Media conditioned by MAC-T cells contained four forms of IGFBP that were identified, by western blotting with specific antibodies, as IGFBP-2, -3, -4 and -6. The amounts of IGFBP-3 in conditioned media were relatively low under basal conditions when analyzed by ligand blotting with 125I-IGF-II, but were increased dramatically relative to serum-free controls by exposure to IGF-I (100 ng/ml) or IGF-II (100 ng/ml) for 24 h. These increases in IGFBP-3 protein corresponded with dose-dependent increases in IGFBP-3 mRNA, with IGF-II eliciting a smaller response than was elicited by IGF-I at each concentration. Leu-IGF-I, which has reduced affinity for the IGF-I receptor but normal affinity for IGFBPs, failed to increase IGFBP-3 protein and mRNA levels, whereas B-chain IGF-I (normal affinity for the receptor but reduced affinity for IGFBPs) elicited the response, thus implying an IGF-I receptor-mediated event. Time-course studies indicated that IGFBP-3 mRNA was increased fourfold by 3 h of IGF-I treatment, with maximal increases of eightfold above serum-free controls observed between 8 and 13 h of treatment. By 24 h of treatment, IGFBP-3 mRNA levels had declined and were approximately threefold above controls in cells exposed to IGF-I. Amounts of messenger RNA of IGFBP-6 and IGFBP-2 were not increased by IGF treatment. However, retinoic acid (10(-6) M) stimulated both IGFBP-2 and IGFBP-6 protein and mRNA levels, but it decreased IGFBP-3 mRNA levels relative to controls. The combination of retinoic acid plus IGF-I had no additional effect on IGFBP-6 or -2 above that observed with retinoic acid alone, whereas IGF-I together with retinoic acid attenuated the decrease in IGFBP-3 observed with retinoic acid alone. Protein kinase A-mediated pathways were also shown to alter IGFBP synthesis. Forskolin, which increases cAMP, increased IGFBP-3 protein and mRNA levels. The combination of IGF-I plus forskolin resulted in greater increases in both protein and mRNA than were observed with either treatment alone. In contrast, forskolin decreased IGFBP-6 mRNA relative to controls, but had no effect on IGFBP-2. The decrease in IGFBP-6 was less marked when cells were treated with a combination of IGF-I and forskolin. Forskolin had no effect on IGFBP-2 mRNA levels. In summary, the ability of IGF-I specifically to regulate IGFBP-3 synthesis represents a mechanism whereby IGF-I may regulate its own bioactivity. In addition, the differential regulation of IGFBP-2, -3 and -6 by retinoic acid (which inhibits proliferation) and IGF-I (which stimulates proliferation) suggests that these forms of IGFBP have different roles in regulating mammary epithelial cell physiology.


Subject(s)
Insulin-Like Growth Factor Binding Proteins/biosynthesis , Insulin-Like Growth Factor I/pharmacology , Mammary Glands, Animal/metabolism , Animals , Blotting, Northern , Blotting, Western , Cattle , Cell Line , Colforsin/pharmacology , Cyclic AMP/metabolism , Epithelium/drug effects , Epithelium/metabolism , Female , Insulin-Like Growth Factor Binding Protein 2/analysis , Insulin-Like Growth Factor Binding Protein 2/biosynthesis , Insulin-Like Growth Factor Binding Protein 2/genetics , Insulin-Like Growth Factor Binding Protein 3/analysis , Insulin-Like Growth Factor Binding Protein 3/biosynthesis , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 4/analysis , Insulin-Like Growth Factor Binding Protein 4/biosynthesis , Insulin-Like Growth Factor Binding Protein 4/genetics , Insulin-Like Growth Factor Binding Protein 6/analysis , Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Proteins/analysis , Insulin-Like Growth Factor Binding Proteins/genetics , Insulin-Like Growth Factor I/metabolism , Mammary Glands, Animal/drug effects , Polymerase Chain Reaction , RNA, Messenger/analysis , Tretinoin/pharmacology
20.
Mol Cell Endocrinol ; 137(1): 69-78, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9607730

ABSTRACT

The mitogenic and metabolic activities of insulin-like growth factors (IGF) are modulated by a family of six high affinity IGF binding proteins (IGFBPs). This study describes the expression of the mouse IGFBP-6 which is unique among IGFBPs in its preferential binding of IGF II, in insect cells using the baculovirus system. The purified, O-glycosylated IGFBP-6 was functional as shown by IGF binding and by inhibition of IGF II-stimulated DNA synthesis in human fibroblasts. Specific antibodies generated in chicken against the recombinant IGFBP-6 were used for Western blotting analysis and immunohistochemistry. Strong immunoreactivity was found in ossifying bones of the cranial base, in cell clusters of the pancreas anlage, in the trigeminal ganglion, on myoblasts, on motoneurons of the spinal cord of embryonic mice. In tissues of adult mouse, strong IGFBP-6 immunostaining was present in epidermal and peridermal layers of the skin, in meningeal layers, in long-striated skeletal muscle, and in the Langerhans' islets of the pancreas. No immunopositive staining was observed in lung and liver indicating that sites of synthesis and IGFBP action are different.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/biosynthesis , Insulin-Like Growth Factor Binding Protein 6/isolation & purification , Animals , Antibody Specificity , Baculoviridae/genetics , Chickens , Humans , Immune Sera/biosynthesis , Immunohistochemistry , Insecta , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Protein 6/immunology , Mice , Molecular Weight , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...